Navigation Links
Placenta-derived stem cells may help sufferers of lung diseases
Date:7/27/2009

Tampa, Fla. (July 27, 2009) An Italian research team, publishing in the current issue of Cell Transplantation (18:4), which is now available on-line without charge at http://www.ingentaconnect.com/content/cog/ct, has found that stem cells derived from human placenta may ultimately play a role in the treatment of lung diseases, such as pulmonary fibrosis and fibrotic diseases caused by tuberculosis, chemical exposure, radiation or pathogens. These diseases can ultimately lead to loss of normal lung tissue and organ failure. No known therapy effectively reverses or stops the fibrotic process.

Placenta-derived stem cells are known to be able to engraft in solid organs, including the lungs. Human term placenta stem cells also demonstrate characteristics of high plasticity and low immunogenicity.

"The potential application of fetal membrane-derived cells as a therapeutic tool for disorders characterized by inflammation and fibrosis is supported in previous studies," says Dr. Ornella Parolini, the study's lead author. "In line with the hypothesis that cells derived from the amniotic membrane have immunomodulatory properties and have been used as an anti-inflammatory agent, we set out to evaluate the effects of fetal membrane-derived cell transplantation in chemically-treated (bleomycin) mice."

According to Dr. Parolini, cells delivered via intra-peritoneal transplant, regardless of the cells being allogenic or xenogenic (host's own cells or from another individual respectively), the procedure resulted in a significant anti-fibrotic effect on the lab animals. A "consistent" reduction in lung fibrosis, says Dr. Parolini, "provides convincing proof" that placenta-derived cells do confer benefits for bleomycin-induced lung injury. While the severity of inflammation did not show an overall reduction, there was a marked reduction in neutrophil (white blood cell) infiltration after both xeno-and-allo-transplantation.

"It is worth noting," says Dr. Parolini," that the presence of neutrophils is associated with poor prognosis for several lung diseases. However, the mechanism by which placenta-derived cells might affect infiltration by neutrophils is not known."

The researchers speculated that these cells may produce soluble factors that induce anti-inflammatory effects.

"Our findings suggest that fetal membrane-derived cells may prove useful for cell therapy of fibrotic diseases in the future," concludes Dr. Parolini.

Dr. Cesar Borlongan, of the University of South Florida and associate editor for Cell Transplantation, notes that the present study adds an important application of placenta cells, indicating their therapeutic effects in lung diseases. The cells' ability to reduce neutrophils possibly via secreted anti-inflammatory factors implies their use either as autografts or allografts, thereby increasing the numbers of the target patient population.


'/>"/>

Contact: Ornella Parolini
ornella.parolini@tin.it
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. ESF EURYI award winner aims to stop cancer cells reading their own DNA
2. Newly created cancer stem cells could aid breast cancer research
3. AIDS interferes with stem cells in the brain
4. Clemson scientists shed light on molecules in living cells
5. Social habits of cells may hold key to fighting diseases
6. UF scientists reveal how dietary restriction cleans cells
7. Human derived stem cells can repair rat hearts damaged by heart attack
8. Scientists identify embryonic stem cells by appearance alone
9. Cells united against cancer
10. Pittsburgh scientists identify human source of stem cells with potential to repair muscle
11. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2020)... ... 21, 2020 , ... Lifecycle Biotechnologies announces the new line of high purity powder ... based on their process requirements and accurately weighed to 0.001 of a gram. The new ... , Sugars , Carbohydrates , Phosphates , ...
(Date:1/8/2020)... Ariz. (PRWEB) , ... January 08, 2020 , ... ... therapies, is now offering complimentary overnight shipping to its nationwide practice network ... biologics, but also due to volume in its Network the biologics themselves are ...
(Date:1/2/2020)... , ... January 02, 2020 , ... ... semi-custom aqueous reagents, chemicals, and medias, as well as medical grade plastic products ... and tissue-based product manufacturers. , “We are excited to bring even more ...
Breaking Biology News(10 mins):
(Date:2/5/2020)... ... February 04, 2020 , ... Shoreline Biome , a ... strain level, has announced a new distribution partnership in Asia. , The distribution ... to companies and research organizations in China, Hong Kong, and Macau. , Gene ...
(Date:1/28/2020)... ... January 28, 2020 , ... Genedata, ... the release of Genedata Expressionist ® 13.5 at the 2020 WCBP ... Methods (MAM) for characterizing and monitoring the quality of biopharmaceuticals throughout their ...
(Date:1/24/2020)... ... January 24, 2020 , ... The ... in biotechnology, diagnostics, therapeutics, laboratory and clinical services during the first two decades ... the world. And as Slone Partners celebrates its 20th anniversary this ...
(Date:1/22/2020)... ... January 21, 2020 , ... COBO Technologies and Cardea ... The partners have agreed to co-develop and market a portfolio of CRISPR QC ... programs. Over the longer-term, the parties aim to develop a COBO branded QC ...
Breaking Biology Technology: